Raising the bar in haemophilia A care

For people living with haemophilia A, every bleed matters. Though rare, the condition affects approximately 10,000 people in the UK, along with their families and loved ones.1 Haemophilia A occurs when the body lacks or has insufficient factor VIII, a clotting protein, which can lead to uncontrolled bleeding.2

Decades of scientific innovation have significantly advanced our understanding of the condition, leading to a broad range of treatment options and personalised approaches to patient care. But the journey is not over. We need to continue to challenge current thinking and approaches to meet the evolving needs of people with haemophilia A.

Progress doesn’t erase the human experience of haemophilia A. Even as science advances, people still face physical, emotional and logistical burdens that influence daily decision and shape their lives. The definition of ‘unmet need’ itself evolves not only across a person’s life, but also when advances in treatment raise expectations and reveal new challenges that were previously hidden.

Despite the availability of preventative (prophylactic) therapies, some people with haemophilia A still experience bleeds and long-term complications such as chronic joint damage and haemarthrosis (bleeding into joints causing pain and swelling).2 Beyond physical symptoms, haemophilia A can limit spontaneity and add logistical or financial strain – all pressures that evolve as life changes, from school to work to family. Fear of bleeds and vigilant contingency planning can be overwhelming.

Acknowledging the ongoing burden compels us to ask harder questions: how to ensure that innovation translates into meaningful improvements for everyone living with haemophilia A, regardless of circumstances or location.

The haemophilia A community has seen remarkable progress, but work is far from complete. Each advancement opens new possibilities – and new challenges. Meeting them requires sustained long-term commitment and the bringing together of expertise from many different spheres.

Investment in research and development, rooted in the real and evolving needs of people living with haemophilia A, is essential to address unmet needs across a broad range of patient populations. But advancing haemophilia A care demands broad, multi-stakeholder collaboration, including patients and families, scientists, manufacturers, regulators, health technology assessors, patient organisations, and multidisciplinary care teams, all working together.

We recognise that managing haemophilia A is a lifelong journey. For over 20 years, our teams have been part of the haematology landscape, contributing to the global scientific understanding of bleeding disorders. We remain dedicated to working alongside the haemophilia A community to understand the evolving challenges faced by those living with this condition.

We believe the future of care is built on sustained partnership and a shared dedication to improving the lives of people affected by haemophilia.